Department of Dermatology, STD and Leprosy, S. M. H. S. Hospital, Srinagar, Jammu and Kashmir, India.
Indian J Dermatol Venereol Leprol. 2010 Nov-Dec;76(6):662-5. doi: 10.4103/0378-6323.72462.
Psoriasis is a chronic inflammatory disease of the skin and is associated with an increased risk of cardiovascular atherosclerosis. Metabolic syndrome, a conglomerate of various clinical and biochemical parameters is a significant predictor of atherosclerotic disease and the associated risk for cardiovascular events in such patients.
To investigate the prevalence of metabolic syndrome in patients with psoriasis.
The study was a prospective, hospital based case-control study involving 150 adult patients with chronic plaque psoriasis and 150 healthy controls. Venous samples were taken at the enrollment visit after the subjects had fasted overnight (at least 8 h). Serum cholesterol and triglycerides were measured with enzymatic procedures. Plasma glucose was measured using a glucose oxidase method. Metabolic syndrome was diagnosed by the presence of three or more criteria of the National Cholesterol Education Programme's Adult Panel III (ATP III). Statistical analysis of the data was done using statistical processing software (SPSS-17) and epi-info software.
Metabolic syndrome was significantly more common in psoriatic patients than in controls 42(28%) vs 9(6%), odds ratio (OR) = 6.09, P<0.05. Psoriatic patients also had a significantly higher prevalence of hypertriglyceridaemia (73/150 among cases vs 24/150 among controls; P<0.05), arterial hypertension (74/150 among cases vs 24/150 among controls; P<0.05) and impaired fasting plasma glucose levels (27/150 among cases vs 04/150 among controls; P<0.05). Psoriatic patients with metabolic syndrome had mean disease duration of 13.67±11.87 years against 6.46±5.80 years in those without metabolic syndrome.
There is a significantly higher prevalence of metabolic syndrome in psoriasis patients as compared to general population and so is the risk of having atherosclerotic adversity. While managing the psoriatic plaques of these patients, concerns should extend to the atherosclerotic plaques as well.
银屑病是一种慢性炎症性皮肤病，与心血管动脉粥样硬化的风险增加有关。代谢综合征是各种临床和生化参数的综合，是动脉粥样硬化疾病的重要预测因子，也是此类患者心血管事件相关风险的重要预测因子。
调查银屑病患者代谢综合征的患病率。
该研究为前瞻性、基于医院的病例对照研究，纳入 150 例慢性斑块状银屑病成年患者和 150 名健康对照者。在受试者禁食至少 8 小时后于入院就诊时采集静脉样本。采用酶法检测血清胆固醇和甘油三酯，葡萄糖氧化酶法检测血浆葡萄糖。采用美国国家胆固醇教育计划成人治疗专家组（ATP III）的三项或以上标准诊断代谢综合征。使用统计处理软件（SPSS-17）和 epi-info 软件对数据进行统计分析。
与对照组相比，银屑病患者代谢综合征的发生率显著更高[42（28%）比 9（6%）]，比值比（OR）=6.09，P<0.05。银屑病患者也有更高的高甘油三酯血症发生率[73/150（49%）比 24/150（16%）]，动脉高血压发生率[74/150（49%）比 24/150（16%）]和空腹血糖受损发生率[27/150（18%）比 04/150（3%）]，差异均有统计学意义（P<0.05）。患有代谢综合征的银屑病患者的平均疾病持续时间为 13.67±11.87 年，而无代谢综合征的患者为 6.46±5.80 年。
银屑病患者代谢综合征的患病率明显高于普通人群，患动脉粥样硬化不良事件的风险也相应增加。在治疗这些患者的银屑病斑块的同时，也应关注动脉粥样硬化斑块。
